Thomas Kotarakos
Fortuna: - $ al 30/06/2026
Fortuna: - $ al 30/06/2026
Thomas Kotarakos is Chief Financial Officer at Parabilis Medicines, Inc. starting in 2026.
Formerly, Mr. Kotarakos was Controller at Seres Therapeutics, Inc. from 2014 to 2018 and Senior VP-Finance & Business Operations at Codiak BioSciences, Inc. from 2018 to 2021.
Education includes undergraduate and graduate degrees from Bentley University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 10/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| PARABILIS MEDICINES, INC. | Director Financiero/CFO | 10/12/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
| CODIAK BIOSCIENCES | Corporate Officer/Principal | 01/12/2021 |
| SERES THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/10/2018 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Bentley University
Bentley University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seres Therapeutics, Inc.
Seres Therapeutics, Inc. BiotechnologyHealth Technology Develops novel treatments for diseases related to the human microbiome | Health Technology |
Parabilis Medicines
Parabilis Medicines Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for cancers and tumors | Health Technology |
Codiak BioSciences, Inc.
Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops exosome based therapeutics | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.